Johnson & Johnson (J&J, NYSE: JNJ) announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval to Rybrevant Faspro (amivantamab and hyaluronidase‑lpuj; subcutaneous injection, 160 mg/2,000 units per mL) as a single agent for adults with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) whose disease progressed on or after platinum‑based chemotherapy and an anti‑PD‑(L)1 antibody — the first approval of a dual‑targeted therapy in this setting.
Regulatory Milestone
| Item | Detail |
|---|---|
| Agency | U.S. Food and Drug Administration (FDA) |
| Approval Type | Accelerated approval |
| Product | Rybrevant Faspro (amivantamab and hyaluronidase‑lpuj), subcutaneous injection, 160 mg/2,000 units per mL |
| Indication | Single‑agent treatment of adults with recurrent or metastatic HNSCC progressing on or after platinum‑based chemotherapy and an anti‑PD‑(L)1 antibody |
| Population Excluded | Patients with HPV‑associated oropharyngeal squamous cell carcinoma (OPSCC), i.e., p16‑positive by immunohistochemistry |
| Approval Date | 5 Nov 2026 |
| Next Steps | Continued approval may be contingent upon verification of clinical benefit in confirmatory trials, per FDA accelerated‑approval requirements |
Drug Profile & Mechanism of Action
- Molecule: Rybrevant Faspro is the subcutaneous formulation of Rybrevant (amivantamab‑vmjw), co‑formulated with hyaluronidase‑lpuj to enable SC delivery.
- Target: EGFR (epidermal growth factor receptor) and MET (mesenchymal‑epithelial transition) — the first approved therapy in this setting to simultaneously target both receptors.
- First‑in‑Class Design: Rybrevant is a first‑in‑class, fully human bispecific antibody with immune cell‑directing activity, combining receptor blockade with engagement of the innate immune system.
- Route‑of‑Administration Advantage: Subcutaneous injection offers a more convenient alternative to intravenous infusion for patients and infusion centers.
- Established Franchise: Rybrevant Faspro has been approved in the U.S. for the same indications as intravenous Rybrevant, which is marketed across multiple global markets.
Clinical Evidence – Phase 1b/2 OrigAMI‑4 Trial
| Endpoint | Result (Cohort 1) |
|---|---|
| Study Population | 102 adults with previously treated recurrent/metastatic HNSCC (post platinum chemotherapy and anti‑PD‑(L)1 antibody; HPV‑positive OPSCC excluded) |
| Confirmed Overall Response Rate (ORR) | 42 % |
| Complete Response Rate | 15 % of patients |
| Durability | 56 % of responders maintained response for more than six months |
| Comparator | None – single‑arm cohort |
The multi‑cohort Phase 1b/2 OrigAMI‑4 trial supported the accelerated approval. Cohort 1 evaluated Rybrevant Faspro as a single agent in the 102‑patient late‑line population described above, with confirmed ORR and duration of response serving as the basis for the accelerated pathway.
Market Impact & Outlook
- Unmet Need in Late‑Line HNSCC: Patients progressing after both platinum chemotherapy and anti‑PD‑(L)1 immunotherapy face limited approved options and poor outcomes; Rybrevant Faspro introduces a new mechanism of action to this difficult‑to‑treat setting.
- First Dual‑Targeted Approval: By hitting EGFR and MET simultaneously, the therapy addresses a resistance axis commonly implicated in head and neck cancers, differentiating it from single‑target agents.
- Franchise Expansion: The approval extends the Rybrevant platform into a new solid‑tumor indication, leveraging an already‑established subcutaneous formulation.
- Precise Patient Selection: The label excludes HPV‑associated (p16‑positive) OPSCC, making p16 immunohistochemistry testing a practical step in identifying eligible patients.
- Regulatory Pathway: Accelerated approval enables earlier patient access, with confirmatory evidence expected to determine whether full approval follows.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding regulatory timelines, confirmatory trial outcomes, and commercial expectations for Rybrevant Faspro in recurrent or metastatic HNSCC. Actual results may differ due to risks including the outcome of post‑approval confirmatory studies, continued‑approval decisions, market adoption, and competitive dynamics.-Fineline Info & Tech
